OncoTargets and Therapy (Oct 2023)

Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer

  • Chen L,
  • Meng Z,
  • Zhou Z,
  • Li X,
  • Zhao L,
  • Jia Z,
  • Chen J,
  • Tian Y,
  • Meng Q,
  • Liu Y

Journal volume & issue
Vol. Volume 16
pp. 885 – 890

Abstract

Read online

Ling Chen,1,* Zhe Meng,2,* Zhiguo Zhou,1,* Xiaomin Li,2 Liyan Zhao,2 Zhaohui Jia,2 Jingli Chen,3 Ye Tian,3 Qingju Meng,2 Yibing Liu1 1The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, 050011, People’s Republic of China; 2The First Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei Province, 054000, People’s Republic of China; 3Hebei Medical University, Shijiangzhuang, Hebei Province, 050011, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yibing Liu, Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, 12 JianKang Road, Shijiazhuang, Hebei Province, 050011, People’s Republic of China, Tel +86-13831173220, Email [email protected] Qingju Meng, Department of Orthopedics, The First Affiliated Hospital of Xingtai Medical College, 376 Shun de Road, Qiaodong District, Xingtai, Hebei Province, People’s Republic of China, Tel +86-13780444436, Email [email protected]: Metaplastic breast cancer (MBC) is a rare disease, and there was rarely reported the treatment after recurrence and metastasis. Here, we report the treatment of an adult patient who suffered from MBC with lung, lymph nodes and left pleura metastasis after radical surgery. The next-generation sequencing result demonstrated that it had tumor mutational burden (TMB) of 12.0 Muts/Mb and microsatellite stability. The patient received sintilimab, an immune checkpoint inhibitor, plus chemotherapy and achieved partial response (PR). This is a report of a good outcome of metastatic MBC achieving 24 months of progression-free survival (PFS) and 39 months of overall survival (OS) with a combination therapy of immune checkpoint inhibitor and chemotherapy. Immuno-chemotherapy may have antitumor activity for relapse MBC. TMB may serve as a potential predictor associated with PD-1 inhibitors in MBC and help clinicians make an optimum treatment strategy.Keywords: metaplastic breast cancer, tumor mutational burden, immunotherapy, chemotherapy, progression-free survival, overall survival

Keywords